Pulmonology & Allergology

The Genuair® products offer patients not only a plus in lung function1,2 but also a distinct improvement in early morning3,4 and nighttime3,4 symptoms. The active ingredients are administered with the help of the prefilled Genuair® inhaler - which also provides patients with confirmation that they have successfully inhaled their medication through the dual feedback mechanism.5,6

References: 1 Sethi S et al.; International Journal of COPD 2019: 14 667-682; 2 Beier J et al.; COPD. 2013 Aug 1; 10(4): 511–522.; 3 Beier J et al.; 2017, International Journal of COPD 2017:12 1731–1740; 4 Kostikas K et al., International Journal of Chronic Obstructive Pulmonary Disease 2022:17 2027–2041;  5 SmPC Brimica® Genuair®; 6 SmPC Bretaris® Genuair®

AT-WEB-10-05-2023


Bretaris® Genuair®

Bretaris® Genuair® (aclidinium bromide) is a long-acting muscarinic receptor antagonist (LAMA) indicated as a continuous bronchodilator therapy for symptom relief in adults with COPD.

Inhaled twice daily via a prefilled, ready-to-use inhaler (Genuair®) with audible and visual feedback mechanisms. In addition to the patient-friendly inhaler, Bretaris® Genuair® is particularly characterized by an improvement in daytime and nighttime symptoms1,2,3 in COPD. No dose adjustment is required in renal impairment and elderly patients.1

Bretaris® Genuair® also shows sustained efficacy and good tolerability over a longer treatment period (52 weeks).4

References: 1 Bretaris® Genuair® Drug information; 2 Fuhr et al., CHEST 2012; 141(3):745–752; 3 Beier et al., Journal of COPD 2013;10(4):511–522; 4 D´Urzo et al., Journal of COPD 2013; 10(4):500–510

AT-WEB-02-10-2021

 

Brimica® Genuair®

Brimica® Genuair® is a fixed combination of the long-acting muscarinic receptor antagonist aclidinium bromide with formoterol fumarate, an established long-acting beta-2 agonist, approved as twice-daily bronchodilator maintenance therapy for symptom relief in adults with COPD.5 

Comparative studies with other bronchodilators6,7 show a clear advantage of twice-daily inhalation over once-daily administration. The LAMA/LABA fixed combination of aclidinium and formoterol offers patients not only a plus in lung function, but also a significant improvement in symptoms.6,8 The active ingredients are administered using the prefilled Genuair® inhaler.5

References: 5 Brimica® Genuair® Drug information; 6 Sethi S et al.: International Journal of COPD 2019: 14: 667–682; 7 Beier J et al.: Int J COPD 2017: 12:1731–1740; 8 D’Urzo et al. Respiratory Research 2014, 15:123

AT-WEB-03-10-2021

menarini-austria-bretaris







menarini-austria-brimica

The Genuair® inhaler

Genuair® is an intuitive, simple and patient-friendly inhaler for use even in severe COPD.

It is a breath-controlled multidose dry powder inhaler that effectively delivers the active ingredients aclidinium bromide (Bretaris® Genuair®) and the combination of the active ingredients aclidinium and formoterol (Brimica® Genuair®) to their site of action.

 

The inhaler can be operated in two simple steps:

  1. Press and release the button
  2. Inhale

 

menarini-austria-genuair-schema

 

The Genuair® inhaler has two feedback mechanisms that provide patients with confirmation that they have successfully inhaled their medication:

  • Audible click after successful inhalation
  • Color change from green to red in the control window

A locking mechanism after the last inhalation prevents the patient from inhaling from an empty Genuair®.  

AT-WEB-03-10-2021

Bretaris® Genuair® is available in the following package sizes and dosages:
1 inhaler with 60 doses - 322 µg.

Brimica® Genuair® is available in the following package sizes and dosages:
1 inhaler with 60 doses - 340 µg/12 µg






Dear visitor, the gender form selected on our homepage always refers to female, male and various people at the same time. We have refrained from using a gender-specific spelling or multiple designations solely for the purpose of better readability. All personal designations are to be understood as gender-neutral.

Liebe Besucherin, lieber Besucher, die auf unserer Homepage gewählte Geschlechtsform bezieht sich immer zugleich auf weibliche, männliche und diverse Personen. Wir haben ausschließlich zum Zweck der besseren Lesbarkeit auf eine geschlechtsspezifische Schreibweise bzw. auf eine Mehrfachbezeichnung verzichtet. Alle personenbezogenen Bezeichnungen sind geschlechtsneutral zu verstehen.

A. Menarini Pharma Gesellschaft mit beschränkter Haftung
Firmenbuchnummer: FN 177062k
Firmenbuchgericht: Handelsgericht Wien
UID-Nummer: ATU 46203601

A. Menarini Pharma limited liability company
Commercial register number: FN 177062k
Commercial register court: Commercial Court Vienna
VAT-Number: ATU 46203601

© 2024 Menarini Austria - All rights reserved